Eli Lilly’s Oral Pill Matches Injectable GLP-1 Drugs in Phase 3 Diabetes Trials

Phase 3 data show similar glycemic control to injectables with equivalent weight loss effectiveness, paving the way for an FDA filing by the end of 2025